22 May 2019 Entyvio® (vedolizumab) Approved in Japan for the Treatment of Patients with Moderately to Severely Active Crohn's Disease
22 May 2019 argenx announces pipeline expansion and “argenx 2021” vision to build integrated immunology company at 2019 R&D Day
21 May 2019 Compugen Doses First Patient in COM701/Opdivo® (Nivolumab) Combination Arm of Phase 1 Study in Patients With Advanced Solid Tumors
21 May 2019 Rainier Therapeutics Announces Presentation of Patient Biopsy Data Demonstrating Vofatamab’s Ability to Increase Immune Cell Activation
21 May 2019 Merck Provides Update on Phase 3 KEYNOTE-119 Study of KEYTRUDA® (pembrolizumab) Monotherapy in Previously-Treated Patients with Metastatic Triple-Negative Breast Cancer
18 May 2019 Primary Endpoint of L-MIND, a Combination Study of Tafasitamab (MOR208) and Lenalidomide, has been met, Confirming Previously Published Activity
18 May 2019 AbbVie Provides Update on Depatuxizumab Mafodotin (Depatux-M), an Investigational Medicine for Newly Diagnosed Glioblastoma, an Aggressive Form of Brain Cancer
15 May 2019 NeuClone to Initiate Phase I Clinical Trial of Stelara (Ustekinumab) Biosimilar, the Second Biosimilar from the 10-product Portfolio with Serum Institute
15 May 2019 ImmunoGen Provides Regulatory Update on Mirvetuximab Soravtansine Monotherapy in Ovarian Cancer
15 May 2019 FDA Approves BAVENCIO® (avelumab) plus Axitinib Combination for Patients with Advanced Renal Cell Carcinoma
14 May 2019 AbbVie Resolves HUMIRA® (adalimumab) U.S. Patent Litigation with Boehringer Ingelheim
14 May 2019 FDA Approves EYLEA® (aflibercept) Injection for Diabetic Retinopathy
13 May 2019 Lilly's CYRAMZA® (ramucirumab) Becomes First FDA-Approved Biomarker-Driven Therapy in Patients with Hepatocellular Carcinoma
12 May 2019 Forty Seven Inc. and Acerta Enter Collaboration to Evaluate Novel Immuno-Oncology Triple Combination in Diffuse Large B-cell Lymphoma
10 May 2019 Merus Announces First Patient Treated in Phase 1 Clinical Trial of MCLA-145 for Advanced Solid Tumors
09 May 2019 U.S. Food & Drug Administration Accepts Takeda’s Biologics License Application for a Subcutaneous Formulation of Vedolizumab (Entyvio®) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
09 May 2019 Bristol-Myers Squibb Announces Phase 3 CheckMate -498 Study Did Not Meet Primary Endpoint of Overall Survival with Opdivo (nivolumab) Plus Radiation in Patients with Newly Diagnosed MGMT-Unmethylated Glioblastoma Multiforme
08 May 2019 Scholar Rock Announces Initiation of Patient Dosing in Phase 2 Trial of SRK-015 in Spinal Muscular Atrophy
08 May 2019 Two Clinical Studies with IBI301, a Biosimilar Candidate to Rituximab, Met Primary Endpoints
08 May 2019 Provention Bio Announces Top-Line Results from its Phase 1b PULSE Clinical Trial of PRV-300 in Patients with Moderate-to-Severe Ulcerative Colitis
08 May 2019 Daiichi Sankyo Announces [Fam-] Trastuzumab Deruxtecan Demonstrated Clinically Meaningful Response in Patients with Refractory HER2 Positive Metastatic Breast Cancer, a Population with High Unmet Need
08 May 2019 Connect Biopharma Reports Positive Phase 1 Data and Announces Initiation of Phase 1b Study in Patients with Atopic Dermatitis for Novel IL-4Rα Antibody CBP-201
07 May 2019 Dupixent® (dupilumab) Approved for Severe Asthma by European Commission
06 May 2019 Xencor Doses First Patient in Phase 1 Study of XmAb®23104 for the Treatment of Patients with Advanced Solid Tumors
06 May 2019 Shattuck Labs, Inc. Announces Initiation of Phase 1 Clinical Trial of SL-279252 (PD1/OX40L)

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up